U10 Full Member Application Affiliated with SWOG
SWOG 附属 U10 正式会员申请
基本信息
- 批准号:8214704
- 负责人:
- 金额:$ 34.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-07-26 至 2015-12-31
- 项目状态:已结题
- 来源:
- 关键词:AwarenessCancer CenterCancer PatientCaringChestClinical InvestigatorClinical Trials Cooperative GroupCollaborationsComprehensive Cancer CenterDevelopmentDisorder by SiteEnsureExhibitsFacultyFutureGrantGroup MeetingsHead and neck structureLeadershipMalignant NeoplasmsManuscriptsMedical OncologyMentorsMissionNCI-Designated Cancer CenterOncologic NursingOncologistOncology NurseOperative Surgical ProceduresPathologistPatientsPharmacologyPhasePositioning AttributePreventionProtocols documentationProviderPublicationsPublishingRadiation OncologistRadiation OncologyRadiation Therapy Oncology GroupReportingResearch PersonnelResourcesRoleServicesSiteSouthwest Oncology GroupSurgeonTexasUniversity of Texas M D Anderson Cancer Centerabstractinganticancer researchcancer therapygroup supportinnovationmembermultidisciplinaryprograms
项目摘要
DESCRIPTION (provided by applicant):
The University of Texas, MD Anderson Cancer Center (MDACC) is one of 3 NCI-designated cancer centers in Texas (and the only one designated as a Comprehensive Cancer Center). MDACC provides comprehensive services to cancer patients through 13 interdisciplinary care centers, integrating medical oncology, surgery, radiation oncology, nursing, pharmacology, and other care providers by disease site/type. During the previous granting period, U10 leadership has been seamlessly transitioned to an internationally recognized clinical investigator and thoracic/head and neck oncologist, Dr. Roy Herbst, with the continued involvement of the former U10 Chair, Dr. Scott Lippman, in the MDACC SWOG Executive committee. As documented in this proposal, MDACC has demonstrated increasing scientific contributions in the previous grant period, with 20 MDACC investigators listed as either primary author or co-author on 42 separate manuscripts and 30 abstracts either published or submitted for publication during this grant period. In addition, 20 investigators have served as either coordinator/co-coordinator of 23 trials in the last grant period, with 6 protocol/protocol concepts currently under development. MDACC has also exhibited year-over-year accrual increases, with 90 patients accrued in 2008, leading to an average accrual in the top third of all SWOG sites. Contributions to SWOG leadership have remained robust over the reporting period; 8 investigators currently hold leadership roles in SWOG, with an additional 5 investigators having held leadership positions in the previous grant period, thus allowing us to provide our multidisciplinary expertise and resources to SWOG, through the involvement of radiation oncologists, surgeons, and pathologists in SWOG leadership positions. MDACC, with significant input from MDACC SWOG staff, also created a Cooperative Group Support Services initiative to ensure awareness of and compliance with cooperative group reporting requirements at an institutional level. Finally, additional contributions include leadership roles in SELECT, PCPT, HIGPN, and other committees; five presentation given by MDACC faculty at Group meetings; and forthcoming intergroup collaborations with RTOG, among others. Future plans for the MDACC SWOG program include the expansion of our SWOG mentoring program for junior faculty. MDACC will continue to apply its strengths in developing multidisciplinary, innovative Phase II and III studies within the SWOG setting. We look fonward to leading SWOG efforts in cancer research, treatment, and prevention; thereby fulfilling our mission of eliminating cancer in Texas, the nation, and the world.
描述(由申请人提供):
德克萨斯大学马里兰州大学癌症中心(MDACC)是德克萨斯州的3个NCI指定的癌症中心之一(也是唯一被指定为综合癌症中心的癌症中心之一)。 MDACC通过13个跨学科护理中心为癌症患者提供全面的服务,并通过疾病部位/类型整合医学肿瘤学,手术,放射肿瘤学,护理,药理学和其他护理提供者。在上一个授予期间,U10领导力已无缝过渡到国际认可的临床调查员,胸部/头颈肿瘤学家Roy Herbst博士,前U10主席Scott Lippman博士继续参与MDACC Swog执行委员会。正如本提案中所记录的那样,MDACC在上一批赠款期间表明了越来越多的科学贡献,在本赠款期间,有20名MDACC调查人员被列为42个单独的手稿和30个发表或提交的摘要,被列为主要作者或合着者。此外,在上一个赠款期间,有20名调查人员担任23个试验的协调员/协调员,目前正在开发6个协议/协议概念。 MDACC还表现出年度应计的增长,2008年有90名患者,导致所有SWOG站点的前三分之一的平均应计。在报告期间,对Swog领导层的贡献保持了强大; 8个调查人员目前在SWOG中担任领导职务,另外5名调查人员在上一个赠款期间担任领导职务,从而使我们能够通过参与辐射肿瘤学家,外科医生,外科医生和病理学家的参与来提供我们的多学科专业知识和资源,以折断领导职位。 MDACC在MDACC SWOG工作人员的大量意见下还制定了一项合作集团支持服务计划,以确保对机构一级的合作集团报告要求的认识并遵守合作。最后,其他贡献包括在Select,PCPT,HIGPN和其他委员会中的领导角色; MDACC教师在小组会议上给出的五个演讲;以及即将与RTOG等组合的合作。 MDACC SWOG计划的未来计划包括扩大我们为初级教师的SWOG指导计划。 MDACC将继续在SWOG环境中发展多学科,创新的II和III研究。我们希望在癌症研究,治疗和预防方面进行领导劳资的努力。从而履行了我们在德克萨斯州,国家和世界上消除癌症的使命。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Cathy Eng其他文献
Cathy Eng的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Cathy Eng', 18)}}的其他基金
UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP)
UT MD 安德森癌症中心网络领导学术参与网站 (LAP)
- 批准号:
9024475 - 财政年份:2014
- 资助金额:
$ 34.12万 - 项目类别:
UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP)
UT MD 安德森癌症中心网络领导学术参与网站 (LAP)
- 批准号:
8838749 - 财政年份:2014
- 资助金额:
$ 34.12万 - 项目类别:
UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP)
UT MD 安德森癌症中心网络领导学术参与网站 (LAP)
- 批准号:
8605951 - 财政年份:2014
- 资助金额:
$ 34.12万 - 项目类别:
Determinants of Efficacy to the Akt Inhibitor Perifosine in Colorectal Cancer
Akt 抑制剂哌立福辛治疗结直肠癌疗效的决定因素
- 批准号:
8294604 - 财政年份:2011
- 资助金额:
$ 34.12万 - 项目类别:
Determinants of Efficacy to the Akt Inhibitor Perifosine in Colorectal Cancer
Akt 抑制剂哌立福辛治疗结直肠癌疗效的决定因素
- 批准号:
8192035 - 财政年份:2011
- 资助金额:
$ 34.12万 - 项目类别:
U10 Full Member Application Affiliated with SWOG
SWOG 附属 U10 正式会员申请
- 批准号:
8408827 - 财政年份:2004
- 资助金额:
$ 34.12万 - 项目类别:
相似国自然基金
以家庭为中心的癌症患儿多症状管理模式的构建及干预:基于症状管理理论的实证研究
- 批准号:71704106
- 批准年份:2017
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Extensible Open Source Zero-Footprint Web Viewer for Cancer Imaging Research
用于癌症成像研究的可扩展开源零足迹 Web 查看器
- 批准号:
10644112 - 财政年份:2023
- 资助金额:
$ 34.12万 - 项目类别:
Raise Awareness In Students Early (RAISE) Host and Microbe Program
早期提高学生意识 (RAISE) 宿主和微生物计划
- 批准号:
10628899 - 财政年份:2023
- 资助金额:
$ 34.12万 - 项目类别:
Fertility experiences among ethnically diverse adolescent and young adult cancer survivors: A population-based study
不同种族青少年和年轻成年癌症幸存者的生育经历:一项基于人群的研究
- 批准号:
10744412 - 财政年份:2023
- 资助金额:
$ 34.12万 - 项目类别:
Validation of novel imaging and molecular tests for early detection of pancreatic cancer through risk-stratified community engagement programs
通过风险分层社区参与计划验证用于早期检测胰腺癌的新型成像和分子测试
- 批准号:
10640704 - 财政年份:2023
- 资助金额:
$ 34.12万 - 项目类别: